SmartCelleTM – Enabling Delivery

Our Technology

SmartCelleTM – Smart Micelles

Intravenous Delivery

SmartCelle dynamic micelles reversibly bind highly insoluble drugs like TA-A001 increasing their solubility many thousand fold while retaining a viscosity close to that of water. Small volume, high concentration injectable solutions are produced which may be terminally filtered or sterilized to generate simple intravenous administration. Once injected the micelles dissociate releasing their payload directly into the blood. Binding of SmartCelle micelles to blood proteins can also increase circulation time.

Ocular Delivery

The small size (30nm) and neutral charge of SmartCelle micelles makes them ideal carriers of drugs across the tear-film and mucins of the eye allowing direct access to the corneal epithelium. Entrapment in the corneal glycocalyx also promotes sustained drug delivery. Access to the rear of the eye via the conjunctiva –scleral route is also enhanced.

Intra-Nasal Delivery

Spray-dried micellar formulations allow intra-nasal delivery and the possibility of direct access to the CNS.

Safety and Tolerability

SmartCelle micelles comprise copolymers of two FDA approved excipients for intravenous administration. The low molecular weight and biodegradability of SmartCelle polymers allows predominantly renal clearance after intravenous administration where bolus injections of over 300mg/kg have been well tolerated in animal models.

CONTACT US

Phone: 514 883 3447

Email: info@tallcinc.com

NEWS

TALLC Corporation Announces Grant of New SmartCelle Patent for
Enhanced Ocular Delivery of TA-A001

Tetra Bio-Pharma and Altus Formulation Form New Company “TALLC” to Exploit TA-A001

TALLC Launches New Ophthalmology Drug WebSite:

https://www.tallcinc.com

TALLC Inc. is an emerging ophthalmology company developing novel mechanism medicines to treat acute and chronic conditions of the eye. Visit our website to learn more about TA-A001,…https://lnkd.in/dTjZ8Nx

Load More...
TALLC Innovation in Vision

© TALLC Inc. 2020